Transdermal Delivery Solutions & ALZYN Announce License for HypoSpray® Delivery of Alzheimers Therapy

Transdermal Delivery Solutions, a leader in the development of
spray-on drug delivery systems, and ALZYN, LLC, an early stage company
focused on addressing Alzheimer’s Disease, announced today they have
signed a license agreement for development of a HypoSpray-delivered
proprietary solution targeted at halting the progression of AD

PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–#AlzheimersTransdermal
Delivery Solutions Corporation
(TDSC) announced today the signing of
a product license arrangement with ALZYN,
LLC of St. Petersburg, FL.

“We are pleased to announce the finalization of our agreement for
this product with the team at ALZYN,” said Kenneth Kirby, President of

About ALZYN’s Approach and AD

ALZYN is a development stage company pursuing a unique approach to
retard the progression of Alzheimer’s disease employing
well-characterized compounds that were licensed from the Florida State
Research Foundation. This new and novel approach was developed by Dr.
Ewa Bienkiewicz, Research Associate Professor and Director of the
Protein Biology Laboratory at Florida State University’s College of
Medicine. She selected and tested several compounds, demonstrating their
efficacy in a proof-of-concept study. She and her team evaluated levels
of several diverse biomarkers associated with the Alzheimer’s disease.
These markers are believed to drive the cascading symptoms of AD as it
progresses. Collectively, the observed modifications in AD pathology
biomarkers reflected a promising therapeutic breakthrough and preventive
strategy to combat this disease. Dr. Bienkiewicz’s findings have been
accepted for peer-reviewed publication in a leading journal. “Dr.
Bienkiewicz’s studies are very encouraging,” said ALZYN Managing
Director Don Rosenkoetter. “The prospect of moving this science from the
lab to the people who so desperately need a safe and efficacious therapy
that will alter the course of this tragic disease engenders a tremendous
passion and energy amongst our team. In TDSC and Langford Research
Institute we have found development partners that both have the
capabilities we were seeking and share our sense of urgency and mission.”

The Nexus of HypoSpray® and AD Research

While these compounds are showing great promise in validated vitro
experiments, dosing is a challenge. The digestive tract very effectively
digests these compounds so creating a concentration high enough to be
effective against the AD beta amyloid peptides in the brain is our
mission. The HypoSpray technology, transdermally bypasses the digestive
tract and enables raising effective dose levels of these compounds. TDSC
and its affiliated research arm, The Langford Research Institute, will
formulate a spray-on solution that is expected to create the blood and
brain levels documented in studies of the individual compounds to be
effective. The formula will be tested first for proof of concept and for
dose levels in patients. “This use of the HypoSpray technology to enable
therapeutic outcomes with these compounds by means of a transdermal
formulation is a significant step for biotechnology compound dosing,”
Kirby stated.

About Transdermal Delivery Solutions (TDSC)

TDSC is committed to advancing the science of transdermal drug delivery
using its patented spray-on delivery system. TDSC’s proprietary system
enables medications to be delivered directly through the skin, for
systemic or localized application, utilizing its rapid acting,
patchless, spray-on technology. No other company can offer similar,
consumer friendly, dosing flexible solutions.


ALZYN is an early stage company committed to reducing the tragedy of
Alzheimer’s. The Company is pursuing a unique and promising approach to
halting the progression of AD. The science, licensed from the Florida
State Science Foundation, is at a preclinical development stage. ALZYN
is being advised by the Newport Board Group.

About Langford Research Institute, Inc.

LRI is a South Florida-based not-for-profit institute dedicated
to supporting the research of TDSC and its affiliates and partners. The
institute is a U.S. FDA-registered Drug Labeler, U.S. DEA Controlled
Substance Researcher and Exporter, an NIH registered facility and a
State of Florida licensed Pharmaceutical Manufacturer. The institute is
a cGMP facility approved to manufacture clinical trial materials.


MarCom Consultant (for TDSC)
Cindy Metzler, 561-429-6429
Don Rosenkoetter, 617-461-6654
Managing Director
Research Institute, Inc.
Kenneth Kirby, 561-429-6429 ext. 104